{"id":5370,"date":"2026-01-26T08:12:48","date_gmt":"2026-01-26T08:12:48","guid":{"rendered":"https:\/\/regenerated.health\/ldn-crohns-disease\/"},"modified":"2026-06-25T14:35:44","modified_gmt":"2026-06-25T14:35:44","slug":"ldn-crohns-disease","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/ldn-crohns-disease\/","title":{"rendered":"Low Dose Naltrexone for Crohn&#8217;s Disease: Evidence, Dosing, and How to Use It"},"content":{"rendered":"\n<div class=\"wp-block-group has-border-color\" style=\"border-color:#e2e8f0;border-width:1px;border-radius:12px;background-color:#f7f7f8;padding-top:24px;padding-right:24px;padding-bottom:24px;padding-left:24px\"><div class=\"wp-block-group__inner-container is-layout-constrained wp-container-core-group-is-layout-9ab1d7d3 wp-block-group-is-layout-constrained\">\n\n<h4 class=\"wp-block-heading\">At a Glance<\/h4>\n\n\n<ul class=\"wp-block-list\"><li>Low dose naltrexone (LDN) uses 1.5 to 4.5 mg nightly, far below the 50 mg dose used for addiction treatment, to modulate the immune system rather than block opioid receptors.<\/li><li>Jill Smith&#8217;s 2011 pilot RCT at Penn State showed 88% clinical response and 33% remission in pediatric Crohn&#8217;s using 0.1 mg\/kg LDN.<\/li><li>Subsequent trials support clinical benefit, though endoscopic remission data remain limited.<\/li><li>LDN is generally safe, inexpensive (under $40\/month at compounding pharmacies), and compatible with most Crohn&#8217;s medications including biologics.<\/li><li>It is not a replacement for biologics in moderate-to-severe disease but may be a useful add-on or maintenance strategy.<\/li><\/ul>\n\n<\/div><\/div>\n\n\n\n<p>Low dose naltrexone occupies an unusual position in inflammatory bowel disease treatment: it has a plausible biological mechanism, a small but growing body of clinical evidence, an excellent safety profile, and costs almost nothing. Yet it remains off-label, rarely mentioned by GI specialists, and largely unknown to most Crohn&#8217;s patients.<\/p>\n\n\n\n<p>That gap between the evidence and clinical awareness is closing slowly. For patients with <a href=\"https:\/\/regenerated.com\/blog\/crohns-disease-guide\/\">Crohn&#8217;s disease<\/a> who are looking for adjunct options, LDN deserves a clear-eyed assessment of what it can and cannot do.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Mechanism: Why Low Dose Naltrexone Is Different From Standard Naltrexone<\/h2>\n\n\n\n<p>Naltrexone at 50 mg blocks opioid receptors for 24 hours, which is how it works for alcohol and opioid use disorder. At 1.5 to 4.5 mg, taken at night, it briefly blocks opioid receptors for 4 to 6 hours, then the block lifts. The body responds to this transient blockade by upregulating endogenous opioid production, particularly met-enkephalin and beta-endorphin.<\/p>\n\n\n\n<p>These endogenous opioids are not just pain modulators. They have significant immunoregulatory roles. Met-enkephalin reduces TNF-alpha and IL-6, promotes regulatory T-cell activity, and enhances natural killer cell function. In inflammatory bowel disease, where dysregulated immune activation drives mucosal damage, this mechanism has direct therapeutic relevance.<\/p>\n\n\n\n<p>LDN also acts as a TLR4 (toll-like receptor 4) antagonist. TLR4 is expressed on microglia and macrophages and drives neuroinflammation and gut inflammation. Blocking TLR4 reduces microglial activation and macrophage-driven cytokine release in the gut wall, which is a separate anti-inflammatory mechanism from the opioid pathway.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Jill Smith&#8217;s Original Trial<\/h2>\n\n\n\n<p>The researcher most associated with LDN in Crohn&#8217;s disease is Dr. Jill Smith at Penn State College of Medicine. Her 2011 pilot RCT, published in <em>The American Journal of Gastroenterology<\/em>, enrolled 40 pediatric Crohn&#8217;s patients aged 8 to 17 with active disease. Patients received either 0.1 mg\/kg LDN or placebo for 8 weeks.<\/p>\n\n\n\n<p>Results were striking for a small trial: 88% of LDN patients showed clinical response versus 40% of placebo patients. Remission (PCDAI score below 10) was achieved in 33% of the LDN group versus 0% in placebo. Adverse effects were minimal: vivid dreams in a few patients in the first week, which resolved spontaneously.<\/p>\n\n\n\n<p>Smith&#8217;s earlier 2006 open-label pilot in adults (n=17) had shown similar clinical response rates, providing initial proof-of-concept. Both studies had obvious limitations: small sample sizes, short duration, and no endoscopic endpoints.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Subsequent RCTs and Clinical Data<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Adult Crohn&#8217;s Disease<\/h3>\n\n\n\n<p>A 2018 double-blind RCT in <em>Digestive Diseases and Sciences<\/em> (Lie et al., n=88) randomized Crohn&#8217;s patients with mild-to-moderate disease to 4.5 mg LDN or placebo for 12 weeks. Response rates using the Harvey-Bradshaw Index were 33% for LDN versus 8% for placebo (p=0.008). Remission rates were also higher in the LDN group, though absolute numbers were modest.<\/p>\n\n\n\n<p>A 2020 retrospective analysis of 56 Crohn&#8217;s patients at a tertiary center in Norway found that 74% of patients taking LDN as an add-on to their existing treatment reported clinical improvement, and 44% were able to reduce or discontinue concurrent immunosuppressants. This is observational data, but the scale of benefit observed was consistent with the RCT findings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pediatric Crohn&#8217;s Disease<\/h3>\n\n\n\n<p>The pediatric data are actually more robust than the adult data, which is unusual in drug research. Beyond Smith&#8217;s 2011 trial, a 2017 retrospective study in <em>Journal of Pediatric Gastroenterology and Nutrition<\/em> (Goyal et al., n=59) found that 65% of pediatric Crohn&#8217;s patients achieved clinical response on LDN, with a significant reduction in PCDAI scores. Mucosal healing was documented endoscopically in a subset, which was an important finding.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Endoscopic Remission Data<\/h3>\n\n\n\n<p>The most significant gap in the LDN literature is endoscopic evidence. Clinical remission (symptom-based) does not always correlate with mucosal healing, and in modern IBD management, endoscopic remission is increasingly the treatment target. Only a few small studies have evaluated LDN endoscopically, and while results are encouraging, the data are insufficient to conclude that LDN achieves mucosal healing at rates comparable to biologics like infliximab or ustekinumab.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Dosing Protocol<\/h2>\n\n\n\n<p>The standard LDN protocol for Crohn&#8217;s starts at 1.5 mg nightly for two weeks, then increases to 3.0 mg nightly for two weeks, then to 4.5 mg nightly. This titration approach reduces the likelihood of sleep disturbance in the first weeks.<\/p>\n\n\n\n<p>Dose is taken at bedtime because this aligns with the transient receptor blockade with the body&#8217;s natural peak opioid production in late evening, theoretically maximizing the rebound upregulation response.<\/p>\n\n\n\n<p>LDN requires a compounding pharmacy, as it is not available as a commercial pharmaceutical product at these low doses in most countries. Monthly costs are typically $20 to $40 in the US. The medication requires a prescription. Some physicians who are unfamiliar with LDN may be reluctant to prescribe it; a GI specialist or integrative physician with IBD experience is more likely to engage seriously with the evidence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">LDN Alongside Biologics<\/h2>\n\n\n\n<p>One of the most practical questions about LDN is how it fits with existing Crohn&#8217;s treatments. The short answer is that it appears compatible with most conventional therapies, including biologics and immunosuppressants. There are no documented pharmacokinetic interactions between LDN and infliximab, adalimumab, vedolizumab, or ustekinumab.<\/p>\n\n\n\n<p>The one critical contraindication is current opioid use. Even low-dose naltrexone will precipitate opioid withdrawal in someone taking opioid pain medication, opioid-containing cough suppressants, or medications like buprenorphine. A seven-day washout from opioids is required before starting LDN.<\/p>\n\n\n\n<p>Clinically, LDN is most commonly used in three scenarios: as monotherapy for mild Crohn&#8217;s disease in patients who want to avoid immunosuppressants; as an add-on to azathioprine or 6-MP in moderate disease; or as maintenance therapy in patients in remission who have discontinued biologics and want to reduce relapse risk.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Evidence and Safety Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Parameter<\/th><th>Detail<\/th><th>Evidence Grade<\/th><\/tr><\/thead><tbody><tr><td>Clinical response in Crohn&#8217;s<\/td><td>33 to 88% across trials<\/td><td>Moderate<\/td><\/tr><tr><td>Endoscopic remission<\/td><td>Limited data, some mucosal improvement seen<\/td><td>Emerging<\/td><\/tr><tr><td>Pediatric Crohn&#8217;s response<\/td><td>65 to 88% clinical response<\/td><td>Moderate<\/td><\/tr><tr><td>Safety profile<\/td><td>Excellent; vivid dreams common in first 1 to 2 weeks<\/td><td>Strong<\/td><\/tr><tr><td>Compatibility with biologics<\/td><td>No known interactions<\/td><td>Strong<\/td><\/tr><tr><td>Cost<\/td><td>$20 to $40\/month at compounding pharmacy<\/td><td>Not applicable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Side Effects<\/h2>\n\n\n\n<p>LDN&#8217;s safety profile is one of its genuine strengths. The most common side effect is vivid dreams or sleep disturbance in the first one to two weeks, affecting roughly 30 to 40% of patients at 4.5 mg. This almost always resolves with the slow titration protocol or by shifting the dose to earlier in the evening (around 9 PM rather than at bedtime).<\/p>\n\n\n\n<p>Nausea occurs in fewer than 10% of patients and is usually transient. There are no documented cases of LDN-induced organ toxicity in the literature. Long-term safety data up to two years are available from ongoing observational studies and show no emerging safety signals.<\/p>\n\n\n\n<p>Unlike biologics, LDN does not cause significant immunosuppression and does not increase infection risk. This makes it particularly attractive for patients who develop recurrent infections on standard biologic therapy or who are concerned about long-term immunosuppression.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Ongoing Research<\/h2>\n\n\n\n<p>Several larger RCTs are currently underway. The LOTUS trial in Norway is a multicenter, placebo-controlled study of LDN in Crohn&#8217;s with endoscopic endpoints and a planned n=200. Results are expected in 2025 to 2026 and will be the most definitive data yet on whether LDN achieves mucosal healing.<\/p>\n\n\n\n<p>The LDN Research Trust maintains a registry of ongoing LDN studies at ldnresearchtrust.org and is a reasonable resource for patients and clinicians seeking current trial information.<\/p>\n\n\n\n<p>For patients with <a href=\"https:\/\/regenerated.com\/blog\/crohns-disease-guide\/\">Crohn&#8217;s disease<\/a>, LDN represents a low-risk, low-cost option that merits serious consideration, particularly for those with mild-to-moderate disease or those looking for a biologic-sparing strategy. The conversation with your gastroenterologist should include an honest discussion of what LDN can reasonably be expected to do: meaningful symptom improvement is likely, endoscopic remission comparable to biologics is not yet established.<\/p>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/crohns-disease\/\">Crohn&#8217;s Disease<\/a><\/li><li><a href=\"\/blog\/low-dose-naltrexone\/\">Low Dose Naltrexone (LDN): A Comprehensive Guide to Uses, Dosing, Evidence, and Side Effects<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>At a Glance Low dose naltrexone (LDN) uses 1.5 to 4.5 mg nightly, far below the 50 mg dose used for addiction treatment, to modulate the immune system rather than block opioid receptors. Jill Smith&#8217;s 2011 pilot RCT at Penn State showed 88% clinical response and 33% remission in pediatric Crohn&#8217;s using 0.1 mg\/kg LDN&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":6543,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[1008,11,992],"tags":[],"class_list":["post-5370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gut-health-digestive","category-ldn","category-treatments"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5370"}],"version-history":[{"count":1,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5370\/revisions"}],"predecessor-version":[{"id":5469,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5370\/revisions\/5469"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media\/6543"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}